C₂N Diagnostics and healthcare company Grupo Fleury have collaborated to bring blood-based tests for early-stage Alzheimer’s diagnosis to Brazil.
The collaboration is aimed at introducing an advanced set of plasma biomarkers that are used to identify changes that indicate the presence of Alzheimer’s disease pathology in people experiencing memory difficulties.
Through this partnership, patients will get access to C₂N Diagnostics’ suite of new blood-based biomarkers, which can detect Alzheimer’s disease at an early stage and without using invasive or radioactive methods.
According to data from the Brazilian Ministry of Health data, there are nearly 1.2 million Alzheimer’s disease cases in Brazil.
Across the world, there are 35.6 million people living with the condition.
C₂N Diagnostics co-founder and scientific advisor Dr Ilana Fogelman said: “Patients deserve early and accurate diagnosis, which represent the first steps toward proper treatment and optimal care planning.
“With Grupo Fleury ’s leadership, we are very much looking forward to bringing our Precivity-related blood testing products to patients in Brazil in a convenient and widely accessible manner.”
Last month, C₂N Diagnostics and Healius collaborated to bring the PrecivityAD blood test and related brain health biomarkers for dementia care to Australia.
The PrecivityAD test helps to determine the likelihood of amyloid plaques in an individual’s brain.
In May, C₂N Diagnostics also took part in the Global Health Care Preparedness Project with the Davos Alzheimer’s Collaborative (DAC ).
In this initiative, DAC announced the launch of seven pilot sites, located in the US, Scotland, Jamaica, Japan, Mexico and Brazil, that will use simple digital cognitive assessment tools, including C₂N Diagnostics’ PrecivityAD blood test, to increase the diagnosis of Alzheimer’s.
Related Companies
